BIOMAT Database Logo BIOMAT Database Logo

Mepolizumab Treatment of Pediatric Eosinophilic Granulomatosis With Polyangiitis. 2018

Mathew X Joseph, and Lauren E Jenkins, and Michael E Wechsler, and Loretta S Davis
Division of Dermatology, Augusta University, Augusta, Georgia.

UI MeSH Term Description Entries
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004803 Eosinophilic Granuloma The most benign and common form of Langerhans-cell histiocytosis which involves localized nodular lesions predominantly of the bones but also of the gastric mucosa, small intestine, lungs, or skin, with infiltration by EOSINOPHILS. Granuloma, Eosinophilic,Eosinophilic Granulomas,Granulomas, Eosinophilic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents
D014890 Granulomatosis with Polyangiitis A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN. Granulomatosis, Wegener's,Wegener Granulomatosis,Wegener's Granulomatosis,Granulomatosis with Polyangiitides,Granulomatosis, Wegener,Polyangiitides, Granulomatosis with,Polyangiitis, Granulomatosis with,with Polyangiitides, Granulomatosis,with Polyangiitis, Granulomatosis
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies

Related Publications

Mathew X Joseph, and Lauren E Jenkins, and Michael E Wechsler, and Loretta S Davis
Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
February 2018, Drugs of today (Barcelona, Spain : 1998),
Mathew X Joseph, and Lauren E Jenkins, and Michael E Wechsler, and Loretta S Davis
Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
July 2019, Expert opinion on biological therapy,
Mathew X Joseph, and Lauren E Jenkins, and Michael E Wechsler, and Loretta S Davis
Vasculitis: Mepolizumab for eosinophilic granulomatosis with polyangiitis.
September 2017, Nature reviews. Rheumatology,
Mathew X Joseph, and Lauren E Jenkins, and Michael E Wechsler, and Loretta S Davis
Mepolizumab to treat eosinophilic granulomatosis with polyangiitis.
February 2024, Medicina clinica,
Mathew X Joseph, and Lauren E Jenkins, and Michael E Wechsler, and Loretta S Davis
Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis.
August 2019, The Journal of allergy and clinical immunology,
Mathew X Joseph, and Lauren E Jenkins, and Michael E Wechsler, and Loretta S Davis
Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis.
March 2023, Pediatric pulmonology,
Mathew X Joseph, and Lauren E Jenkins, and Michael E Wechsler, and Loretta S Davis
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
May 2017, The New England journal of medicine,
Mathew X Joseph, and Lauren E Jenkins, and Michael E Wechsler, and Loretta S Davis
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
May 2024, The New England journal of medicine,
Mathew X Joseph, and Lauren E Jenkins, and Michael E Wechsler, and Loretta S Davis
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
March 2024, The New England journal of medicine,
Mathew X Joseph, and Lauren E Jenkins, and Michael E Wechsler, and Loretta S Davis
Mepolizumab for the Treatment of Eosinophilic Granulomatosis With Polyangiitis: Our Experience.
October 2019, Journal of investigational allergology & clinical immunology,
Copied contents to your clipboard!